【CLAIMS】

【Claim 1】

A health food composition for use in preventing or inhibiting influenza virus infection, comprising ginseng(*Panax ginseng* C.A. Meyer) berry polysaccharides,

wherein the ginseng berry polysaccharides comprise arabinose, galactose, galacturonic acid and glucuronic acid, and

wherein the galacturonic acid and the glucuronic acid are comprised in an amount of 0.1-25 wt% based on the total weight of the ginseng berry polysaccharides.

【Claim 2】

The health food composition according to claim 1, wherein the ginseng berry polysaccharides exhibit reactivity of 40% or higher when treated with a β-glucosyl Yariv reagent with respect to a reference arabino-β-3,6-galactan as 100%.

【Claim 3】

The health food composition according to claim 1, wherein the ginseng berry polysaccharides are derived from water-soluble ingredients in an ethanol-insoluble fraction of ginseng berry.

【Claim 4】

The health food composition according to claim 1, wherein the ginseng berry polysaccharides inhibit the neuraminidase activity of influenza.

【Claim 5】

The health food composition according to claim 1, wherein the influenza comprises one or more of H1N1, H1N2, H2N2, H3N2, H5N1, H6N1, H7N2, H7N3, H7N7, H7N9, H9N2 and H10N7.

【Claim 6】

A pharmaceutical composition for use in preventing or inhibiting influenza virus infection, comprising ginseng(*Panax ginseng* C.A. Meyer) berry polysaccharides,

wherein the ginseng berry polysaccharides comprise arabinose, galactose, galacturonic acid and glucuronic acid, and

wherein the galacturonic acid and the glucuronic acid are comprised in an amount of 0.1-25 wt% based on the total weight of the ginseng berry polysaccharides.

【Claim 7】

The pharmaceutical composition according to claim 6, wherein the ginseng berry polysaccharides exhibit reactivity of 40% or higher when treated with a β-glucosyl Yariv reagent with respect to a reference arabino-β-3,6-galactan as 100%.

【Claim 8】

The pharmaceutical composition according to claim 6, wherein the ginseng berry polysaccharides are derived from water-soluble ingredients in an ethanol-insoluble fraction of ginseng berry.

【Claim 9】

The pharmaceutical composition according to claim 6, wherein the ginseng berry polysaccharides inhibit the neuraminidase activity of influenza.

【Claim 10】

The pharmaceutical composition according to claim 6, wherein the influenza comprises one or more of H1N1, H1N2, H2N2, H3N2, H5N1, H6N1, H7N2, H7N3, H7N7, H7N9, H9N2 and H10N7.